Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:35:31 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



Q:DXR - DAXOR CORP - http://www.daxor.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
DXR - Q3.29.41·12.903.09.65-0.06-0.60.52109.65  9.65  9.6513.128  7.11Apr 26Apr 1615 min RT 2¢

Recent Trades - All 10 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-16 08:00U:DXRNews ReleaseNew Studies Prove the Clinical Benefits of Daxor's Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
2024-04-15 08:00U:DXRNews ReleaseDAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING'24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR'S BLOOD VOLUME DIAGNOSTIC (BVA-100(TM))
2024-04-10 08:00U:DXRNews ReleaseDaxor Corporation Announces New Hospital Account at Leading Chicago Hospital
2024-04-01 08:00U:DXRNews ReleaseDaxor Corporation to Exhibit at the American College of Cardiology for ACC.24
2024-03-25 08:00U:DXRNews ReleaseDaxor Corporation Acquires Volumex(TM) and Megatope(TM) From Its Existing Supplier Along With Glofil(TM) to Enhance Existing Suite of Diagnostics
2024-03-22 08:00U:DXRNews ReleaseDaxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024
2024-03-18 14:18U:DXRNews ReleaseDaxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
2024-03-18 14:18U:DXRNews ReleaseDaxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
2024-03-11 08:00U:DXRNews ReleaseDaxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base
2024-03-08 08:00U:DXRNews ReleaseMulti-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients
2024-02-26 08:00U:DXRNews ReleaseDaxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference
2024-02-12 08:00U:DXRNews ReleaseDaxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions
2024-02-07 08:00U:DXRNews ReleaseDaxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100 ‚ ® Blood Volume Diagnostic Across the U.S. at Existing Accounts
2024-01-29 08:00U:DXRNews ReleaseDaxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting
2024-01-16 08:00U:DXRNews ReleaseDaxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress
2024-01-09 08:00U:DXRNews ReleaseDAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES
2024-01-02 08:30U:DXRNews ReleaseDaxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer
2023-11-13 08:00U:DXRNews ReleaseNew Randomized Controlled Trial Demonstrates the Efficacy of Daxor ¢ € ™s BVA Guided-Care in Heart Failure Patients
2023-11-09 08:00U:DXRNews ReleaseDaxor Corporation Awarded New Patent for Remote Monitoring of Blood Volume
2023-10-13 08:00U:DXRNews ReleaseExpert Panelists Advocate Use of Daxor ¢ € ™s Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting